Apatinib significantly improves both the progression-free survival (PFS) and overall survival in patients with advanced-stage gastric cancer who are refractory to two or more lines of chemotherapy. In the context of previous phase III trials of angiogenesis inhibitors for this disease, we discuss the role of apatinib, and the advantages and limitations of VEGFR-2 blockade in the advanced disease setting.
- Toru Aoyama
- Takaki Yoshikawa
